According to the Wisdom Wealth App, GCI Science & Technology Group Co., Ltd.(02487) increased by more than 4% in early trading, up 3.6% to HKD 8.05 at the time of publication, with a turnover of HKD 2.9247 million.

On the news side, KPC announced recently that its CU-30101 (topical lidocaine and prilocaine cream) pharmaceutical license application has been accepted by the National Medical Products Administration and is expected to make the fastest progress among similar products in the all market; Moreover, on July 12th, the company announced a share re-purchase plan, and has accumulated a total of 5,858,000 shares as of July 30th, representing approximately 0.19% of the total issued share capital.

GF Securities pointed out that the current compliant ratio of hemp paste products is low, and it is expected to occupy the new blue ocean market of compliant topical hemp paste after approval; Short-term commercial drive is strong with high growth stacking of long-term R&D end high barriers, there are multidimensional possibilities of exceeding expectations. Meanwhile, CICC believes that the company has good commercial ability, and multiple pipelines are expected to land in the second half of 2024-2025, bullish on the medium and long-term growth space.